About ExeVir Bio
ExeVir Bio is a company based in Ghent (Belgium) founded in 2020.. ExeVir Bio has raised $49.64 million across 4 funding rounds from investors including European Investment Bank, VIB and European Union. The company has 11 employees as of December 31, 2022. ExeVir Bio offers products and services including VHH Antibody Platform and Antibody Therapies. ExeVir Bio operates in a competitive market with competitors including Pardes Biosciences, Vaxxinity, NRx, Inimmune and IMUNON, among others.
- Headquarter Ghent, Belgium
- Employees 11 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Exevir Bio
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$49.64 M (USD)
in 4 rounds
-
Latest Funding Round
$26.61 M (USD), Debt – Venture
Jan 09, 2023
-
Investors
European Investment Bank
& 10 more
-
Employee Count
11
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ExeVir Bio
ExeVir Bio offers a comprehensive portfolio of products and services, including VHH Antibody Platform and Antibody Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for creating multi-specific antibodies against infectious diseases
Therapies to prevent and treat diseases like COVID-19 and dengue
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ExeVir Bio
ExeVir Bio has successfully raised a total of $49.64M across 4 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $26.61 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Venture — $26.6M
-
First Round
First Round
(28 Jul 2020)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2023 | Amount | Debt – Venture - ExeVir Bio | Valuation |
investors |
|
| Dec, 2021 | Amount | Grant - ExeVir Bio | Valuation |
investors |
|
| Mar, 2021 | Amount | Series A - ExeVir Bio | Valuation | Fund+ |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ExeVir Bio
ExeVir Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, VIB and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location | |
|
Fund+ is focused on investing in life sciences companies.
|
Founded Year | Domain | Location | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ExeVir Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ExeVir Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Exevir Bio Comparisons
Competitors of ExeVir Bio
ExeVir Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pardes Biosciences, Vaxxinity, NRx, Inimmune and IMUNON, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for COVID-19 and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer treatment are developed using DNA-based platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Exevir Bio
Frequently Asked Questions about ExeVir Bio
When was ExeVir Bio founded?
ExeVir Bio was founded in 2020.
Where is ExeVir Bio located?
ExeVir Bio is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Who is the current CEO of ExeVir Bio?
Torsten Mummenbrauer is the current CEO of ExeVir Bio.
Is ExeVir Bio a funded company?
ExeVir Bio is a funded company, having raised a total of $49.64M across 4 funding rounds to date. The company's 1st funding round was a Series A of $22.67M, raised on Jul 28, 2020.
How many employees does ExeVir Bio have?
As of Dec 31, 2022, the latest employee count at ExeVir Bio is 11.
What does ExeVir Bio do?
ExeVir Bio was founded in 2020 in Ghent, Belgium, within the biotechnology sector. Single-domain antibody fragments, known as VHH, derived from camelids are developed for monitoring and addressing viral infections. The lead product, VHH72-FC, targets conserved spike regions of SARS-CoV-2 to inhibit viral entry into cells, halt replication, and aid immune responses by lowering viral loads and reducing inflammation in affected areas.
Who are the top competitors of ExeVir Bio?
ExeVir Bio's top competitors include NRx, Cell BioEngines and Pardes Biosciences.
What products or services does ExeVir Bio offer?
ExeVir Bio offers VHH Antibody Platform and Antibody Therapies.
Who are ExeVir Bio's investors?
ExeVir Bio has 11 investors. Key investors include European Investment Bank, VIB, European Union, Fund+, and UCB Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.